Erudio Healtherudio.com
Indication
Triple-negative breast cancer
1 HCP commentary report on clinical trials in Triple-negative breast cancer. Each report covers what clinicians said in public about one trial, with the source behind every view.
| Trial | Indication | Phase | Statements | HCP sources | Size | Updated | Preview |
|---|---|---|---|---|---|---|---|
| PANKU-Breast02 NCT06382142 · Sichuan Baili Pharmaceutical Co., Ltd. | unresectable locally advanced or metastatic triple-negative breast cancer | Phase 3 | 125 | 28 | Focused | Nov 1, 2026 | Preview |